Price$0.21+0.00 (+0.00%)
2025-11-112026-02-17
News · 26 weeks90%
2025-12-142026-06-07
Mix690d
- SEC Filings3(50%)
- Other3(50%)
Latest news
25 items- SECSEC Form 8-K filed by Bio-Path Holdings Inc.8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECSEC Form 10-Q filed by Bio-Path Holdings Inc.10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECSEC Form NT 10-Q filed by Bio-Path Holdings Inc.NT 10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECSEC Form QUALIF filed by Bio-Path Holdings Inc.QUALIF - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECSEC Form 1-A filed by Bio-Path Holdings Inc.1-A - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECBio-Path Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECSEC Form 1-Z filed by Bio-Path Holdings Inc.1-Z - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECBio-Path Holdings Inc. filed SEC Form 8-K: Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECSEC Form 10-Q filed by Bio-Path Holdings Inc.10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECSEC Form NT 10-Q filed by Bio-Path Holdings Inc.NT 10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECBio-Path Holdings Inc. filed SEC Form 8-K: Leadership Update, Other Events8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECBio-Path Holdings Inc. filed SEC Form 8-K: Leadership Update8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECSEC Form 10-Q filed by Bio-Path Holdings Inc.10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECBio-Path Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECBio-Path Holdings Inc. filed SEC Form 8-K: Leadership Update, Other Events8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- PRLife Sciences Investor Forum: Now Available for Online ViewingNEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th PresentationTicker(s)Nika Pharmaceuticals(OTCQB:NIKA)Tivic Health Systems Inc.(NASDAQ:TIVC)Ad
- PRLife Sciences Investor Forum Agenda Announced for June 11th-12thNEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering co
- PRBio-Path Holdings to Present at Life Sciences Virtual Investor ForumHOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTC:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced Peter Nielsen, Chief Executive Officer, will present a corporate overview at the Life Sciences Virtual Investor Forum on Thursday, June 12 at 12:00 p.m. ET. A live stream of the presentation will be available here and on the Investor Relations section of Bio-Path's website, where it will be archived for approximately 90 days. About Bio-Path Holdings, Inc. Bio-Path is a biotechnology company developing DNAbilize®, a
- PRBio-Path Holdings Provides Clinical and Operational UpdateHOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced highlights from the recent clinical development and operational update conference call and webcast held May 26, 2025. An archived webcast of the event can be accessed here. "Our business model centers around generating new drug candidates from our DNAbilize® platform and licensing them for final development and commercialization with partners that have expertise and scale to successfully bring them to market," sa
- SECSEC Form 253G3 filed by Bio-Path Holdings Inc.253G3 - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECSEC Form QUALIF filed by Bio-Path Holdings Inc.QUALIF - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- PRBio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company's website, www.biopathho
- SECAmendment: SEC Form 1-A/A filed by Bio-Path Holdings Inc.1-A/A - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECSEC Form 10-Q filed by Bio-Path Holdings Inc.10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
- SECBio-Path Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
BPTH FAQ
5 questionsWhat does Bio-Path Holdings Inc. do?
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also developing Liposomal Bcl-2 for the treatment of...Where does BPTH stock trade?
Bio-Path Holdings Inc. (BPTH) is listed on NASDAQ.What sector and industry is BPTH in?
Bio-Path Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to BPTH?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BPTH side-by-side with any of them on Quantisnow.How can I track BPTH on Quantisnow?
Quantisnow aggregates Bio-Path Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BPTH to receive live email and push alerts on every new disclosure.